2022 AHA/ACC/HFSA Guideline for the Management of Heart …
2022年4月1日 · The criteria for diagnosis of HFmrEF and HFpEF require evidence of increased LV filling pressures at rest, exercise, or other provocations. The criteria can be fulfilled with findings of elevated levels of natriuretic peptides, echocardiographic diastolic parameters such as an E/e′ ≥15 or other evidence of elevated filling pressures, or ...
Treatment and prognosis of heart failure with preserved ejection ...
2024年9月18日 · Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome in which patients have signs and symptoms of HF as the result of high left ventricular (LV) filling pressure despite normal or near normal LV ejection fraction (LVEF; ≥50 percent) [1-5].
Heart Failure With Preserved Ejection Fraction (HFpEF)
2024年3月19日 · Diagnosing HFpEF is challenging due to common clinical manifestations and the overlap with other heart failure subtypes. Diagnostic algorithms, such as HFA-PEFF and H2FPEF, along with additional testing like echocardiography and natriuretic peptide measurement, are employed to confirm the diagnosis.
2023 ACC Expert Consensus Decision Pathway on Management of …
HFpEF mimics: Clinical diagnosis of HF and LVEF ≥50% with a primary noncardiac cause (kidney or liver disease) or an underlying cardiac cause (infiltrative cardiomyopathy, hypertrophic cardiomyopathy, valvular disease, pericardial disease, or high-output HF). New York Heart Association (NYHA) functional classification:
2023 ACC Expert Consensus on Management of HFpEF: Key Points
2023年4月19日 · Heart failure with preserved ejection fraction (HFpEF) is defined as signs and symptoms of HF with left ventricular EF (LVEF) ≥50%. Diagnosis and management of HFpEF needs multidisciplinary care involving primary care, cardiology, and HF specialists.
2024 ACC Expert Consensus Decision Pathway for Treatment of …
2024年3月8日 · Sacubitril/valsartan is 1 of the “4 pillars” of medical care for HFrEF. The 2022 AHA/ACC/HFSA HF guideline 2 recommends sacubitril/valsartan as a Class I, Level of Evidence: A therapy to reduce the risk of HF hospitalization and CV mortality in patients with symptomatic chronic HFrEF (Figures 2 and 3, Table 2).
Heart Failure With Preserved Ejection Fraction: JACC Scientific ...
The incidence and prevalence of heart failure with preserved ejection fraction (HFpEF) continue to rise in tandem with the increasing age and burdens of obesity, sedentariness, and cardiometabolic disorders. Despite recent advances in the understanding of its pathophysiological effects on the heart, lungs, and extracardiac tissues, and ...
Heart failure with preserved ejection fraction - Nature
2024年8月14日 · The diagnosis of HFpEF can be made in individuals with signs and symptoms of heart failure with abnormality in natriuretic peptide levels or evidence of cardiopulmonary congestion, facilitated by...
Heart failure with preserved ejection fraction: everything the ...
2024年3月22日 · This algorithm (figure 2) allows for a diagnosis of HFpEF in most patients (approximately 80%) at step 1 whereby a patient with symptoms, with or without signs, of heart failure, or with an LVEF of 50% or higher has a defining feature (eg, detectable congestion or elevated natriuretic peptide levels), and meets at least one of the ...
HFpEF the Focus of New Clinical Guidance - American College of …
2023年5月1日 · With the incidence of heart failure with preserved ejection fraction (HFpEF) on the rise and accounting for more than 50% of all HF cases, a new ACC Expert Consensus Decision Pathway provides important guidance on the diagnosis and management of …